Enzymatic methods for converting LCA and 3-KCA to UDCA and 3-KUDCA

JP2023552528A5Pending Publication Date: 2024-12-06SANDHILL ONE LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023532459
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-30
Filing Date
2021-11-29
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Current methods for converting lithocholic acid (LCA) and 3-keto-5β-cholic acid (3-KCA) to ursodeoxycholic acid (UDCA) and 3-KUDCA suffer from low productivity and incomplete regioselectivity, making them unsuitable for commercial production.

Method used

A yeast-based system is developed that expresses a non-native 7β-hydroxylase activity, utilizing engineered yeast strains transformed with specific CYP and CPR enzymes to efficiently convert LCA and 3-KCA into UDCA and 3-KUDCA, using plasmids encoding nucleic acid sequences with high identity to SEQ ID NOs.

Benefits of technology

The yeast-based system achieves high yields and selectivity in producing UDCA and 3-KUDCA, facilitating scalable and efficient commercial production.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

7β-hydroxylation systems and methods for producing P-hydroxy derivatives of lithocholic acid and 3-keto-lithocholic acid from such systems are provided. Also provided are recombinant organisms useful for producing such enzyme systems and plasmids encoding such enzymes.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to 7β-hydroxylation systems and methods for producing 7β-hydroxyl derivatives of lithocholic acid and 3-keto-5β-cholic acid from such systems. The present invention also relates to recombinant organisms useful for producing such enzyme systems and plasmids encoding such enzymes. [Background technology]

[0002] Ursodeoxycholic acid (UDCA) is a beneficial bile acid frequently prescribed for the treatment of cholecystitis because it can solubilize cholesterol gallstones with fewer side effects than chenodeoxycholic acid (CDCA). UDCA also has anti-inflammatory properties and has been used to treat liver diseases such as cystic fibrosis and primary biliary cholangitis. The primary natural source of UDCA is bile from various species of bears.

[0003] UDCA can also be produced from cholic acid (CA) or CDCA, which can also be obtained from animal bile. Eggert et al. (2014) reported a synthetic route to form CDCA in five steps starting from CA, including Wolff-Kishner ketone reduction and epimerization at C7 to produce UDCA. T. Eggert, D. Bakonyi, W. Hummel, J. Biotechnol. 2014, 191, 11-21. Zheng et al. (2015) reported a shorter synthetic route based on biocatalytic epimerization of CDCA to UDCA. M.-M. Zheng, R.-F. Wang, C.-X. Li, J.-H. Xu, Process Biochem. 2015, 50, 598-604.

[0004] The association of the 7β-hydroxylase system with the cell membrane presents a special challenge for biocatalytic systems. In fact, Durairaj et al. (2016) reported that P450nor is the only soluble fungal CYP discovered so far, which performs denitrification. Durairaj et al. Microb Cell Fact (2016) 15:125. The challenge is further complicated in whole-cell fungi such as Fusarium equiseti, where Grobe et al. (2020) reported that the action of multiple P450 enzymes leads to the formation of by-products. S. Grobe, C. Badenhorst, T. Bayer, et al., Angew. Chem. Int. Ed. 10.1002 / anie.202012675.

[0005] To overcome these hurdles, Grobe et al. (2020) reported the formation of UDCA from LCA in an Escherichia coli-based whole-cell system using a variant of the cytochrome P450 monooxygenase CYP107D1 (oleP) from Streptomyces antibioticus, a P450 enzyme that does not require association with the cell membrane. By modifying the native enzyme that converts LCA to its 6β-hydroxy derivative, MDCA, the authors were able to largely change the position of hydroxylation to favor the formation of UDCA over MDCA. However, the conversion occurred with extremely low productivity (at best 67 μM in 24 h) and incomplete regioselectivity (at best 73:27 UDCA:MDCA ratio).

[0006] Therefore, there is a need for an efficient and productive method for selectively converting LCA and 3-KCA to UDCA and 3-KUDCA. An ideal method would provide high yields, be easy to scale up, and be easy to implement for commercial production. Efficient enzyme systems, methods, and components for the 7β-hydroxylation of lithocholic acid or 3-KCA in commercial quantities are needed. Summary of the Invention

[0007] The present inventors have extensively experimented with various engineered microbial systems for hydroxylating LCA and 3-KCA, including a series of experiments using yeast transformed with native 7β-hydroxylation systems from other species, and have unexpectedly discovered a yeast-based system transformed to express 7β-hydroxylase activity that can selectively produce UDCA and 3-KUDCA and their derivatives from LCA and 3-KCA and their derivatives. Thus, in a first principal embodiment, the present invention provides a method for converting LCA or 3-KCA, or a carboxylic acid ester, carboxylamide, or carboxylate salt thereof, to UDCA or 3-KUDCA, or a carboxylic acid ester, carboxylamide, or carboxylate salt thereof, comprising contacting the LCA or 3-KCA, or the carboxylic acid ester, carboxylamide, or carboxylate salt thereof, with a 7β-hydroxylase system in the presence of yeast, or an extract or lysate thereof, where the 7β-hydroxylase system is not native to the yeast.

[0008] A further main embodiment relates to a plasmid used to generate the organism of the invention. Thus, in a second main embodiment, the invention provides a plasmid comprising a nucleic acid sequence selected from SEQ ID NO:8; SEQ ID NO:11; SEQ ID NO:14; SEQ ID NO:17; SEQ ID NO:20; SEQ ID NO:23; SEQ ID NO:26; SEQ ID NO:29; or SEQ ID NO:32; or a nucleic acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to any of the foregoing sequences.

[0009] Further embodiments relate to transformed organisms for use in the methods of the invention. Thus, in a third main embodiment, the invention provides an organism transformed with a CYP-encoding nucleic acid sequence selected from SEQ ID NO:8; SEQ ID NO:11; SEQ ID NO:14; SEQ ID NO:17; SEQ ID NO:20; SEQ ID NO:23; SEQ ID NO:26; SEQ ID NO:29; and SEQ ID NO:32; or a nucleic acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the foregoing nucleic acid sequences.

[0010] Still further embodiments relate to reaction mixtures in which the conversions of the invention are carried out. Accordingly, in a fourth major embodiment, the invention provides a reaction mixture comprising (i) LCA or 3-KCA, (ii) yeast, or an extract or lysate thereof, and (iii) a 7β-hydroxylation system. In a fifth major embodiment, the invention provides a reaction mixture comprising yeast and a 7β-hydroxylation system comprising a P450 oxidoreductase ("CPR") enzyme and a P450 7β-hydroxylase ("CYP") enzyme, wherein the CYP enzyme is an enzyme native to Gibberella zeae, preferably Gibberella zeae PH1 or Gibberella zeae VKM2600, most preferably Gibberella zeae VKM2600.

[0011] Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. The foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed.

[0012] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and, together with the description, serve to explain the principles of the invention. [Brief explanation of the drawings]

[0013] [Figure 1] 1A-1C illustrate LCMS chromatograms from the experiment described in Example 17. FIG. 1A is a TIC trace of an extracted broth sample. FIG. 1B is a TIC trace of an LCA standard. FIG. 1C is a TIC trace of a UDCA standard. [Figure 2] FIG. 10 is a comparison of the MS spectra of UDCA extracted from broth samples (A) and an authentic standard of UDCA (B), as reported in Example 17. [Figure 3] Figure 3 illustrates CMS chromatograms from the experiment described in Example 18. Figure 3A is a TIC trace of isolated UDCA. Figure 3B is a TIC trace of a UDCA standard. [Figure 4] FIG. 10 is a comparison of the MS spectra of isolated UDCA (A) and UDCA authentic standard (B), as reported in Example 18. [Figure 5] FIG. 1 depicts the 1H NMR spectrum of isolated UDCA from the experiment described in Example 18. [Figure 6] FIG. 13 depicts the 13C NMR spectrum of isolated UDCA from the experiment described in Example 18. [Figure 7]FIG. 13 depicts the 1H NMR spectrum of authentic UDCA from the experiment described in Example 18. [Figure 8] FIG. 13 depicts the 13C NMR spectrum of authentic UDCA from the experiment described in Example 18. [Figure 9] Figures 9A and 9B illustrate LCMS chromatograms from the experiment described in Example 19. Figure 9A is a TIC trace of the extracted broth sample. Figure 9B is an extracted ion chromatogram (EIC) of m / z 389.3 (3-KUDCA) of the extracted broth sample. Figure 9C is a TIC trace of the 3-KUDCA standard. Figure 9D is a TIC trace of the 3-KCA standard. [Figure 10] FIG. 10 is a comparison of the MS spectra of 3-KUDCA extracted from broth samples (A) and an authentic standard of 3-KUDCA (B), as reported in Example 19. [Figure 11] Figures 11A and 11B illustrate LCMS chromatograms from the experiment described in Example 21. Figure 11A is a TIC trace of the extracted broth sample. Figure 11B is an extracted ion chromatogram (EIC) of m / z 391.3 (UDCA) of the extracted broth sample. Figure 11C is a TIC trace of a UDCA standard. [Figure 12] FIG. 10 is a comparison of the MS spectra of UDCA extracted from broth samples (A) and an authentic standard of UDCA (B), as reported in Example 21. DETAILED DESCRIPTION OF THE INVENTION

[0014] Definitions and Use of Terms As used herein and in the claims that follow, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0015] As used in this specification and the claims that follow, the word "comprise" and variations of that word, such as "comprising" and "comprises," mean "including, but not limited to," and are not intended to exclude, for example, other additives, ingredients, integers, or steps. It is understood that when an element is described as comprising multiple ingredients, steps, or conditions, the element may also be described as including any combination of such multiple ingredients, steps, or conditions, or may be described as "consisting of" or "consisting essentially of" multiple ingredients, steps, or conditions, or combinations thereof.

[0016] When a range is given by specifying a lower limit separately from an upper limit of the range or by specifying specific numerical values, it will be understood that the range can be defined by any combination of the lower limit variable, the upper limit variable, and the specific numerical values ​​that is mathematically possible. Similarly, when a range is defined as spanning from one endpoint to the other, it will also be understood that the range encompasses the entire range between and excluding the two endpoints.

[0017] As used herein, the term "about" accounts for variations tolerated in the chemical industry and inherent in products within this industry, such as differences in product strength due to manufacturing variations and time-induced product degradation. In one embodiment, the term allows for a ±5% variation or a ±10% variation.

[0018] The phrase "acceptable" as used in connection with the compositions of the present invention refers to molecular entities and other components of such compositions that are physiologically tolerable and do not normally produce adverse reactions when administered to a subject (e.g., a mammal such as a human).

[0019] "Coding sequence" refers to a portion of a nucleic acid (eg, a gene) that codes for the amino acid sequence of a protein.

[0020] "Naturally-occurring" or "wild-type" or "native" refers to a form found in nature, as opposed to "non-naturally occurring," "non-wild-type," "non-native," or "exogenous." For example, a naturally-occurring or wild-type polypeptide or polynucleotide sequence is a sequence present in an organism that can be isolated from a source in nature and has not been intentionally modified by human manipulation.

[0021] For example, "recombinant" when used in reference to a cell, nucleic acid, or polypeptide refers to a material that has been altered in a manner that would not otherwise occur in nature, or a material that corresponds to the natural or native form of the material. Non-limiting examples include, among others, a recombinant cell expressing a gene that is not found within the native (non-recombinant) form of the cell, or a recombinant cell expressing a native gene that is otherwise expressed at a different level.

[0022] "Percentage of sequence identity" and "percentage of homology" are used interchangeably herein to refer to comparisons between polynucleotides and polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, where the portion of the polynucleotide or polypeptide sequence within the comparison window contains additions or deletions (i.e., gaps) when compared to a reference sequence (which does not contain additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions where the same nucleic acid base or amino acid residue occurs in both sequences to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to obtain the percentage of sequence identity.

[0023] Those skilled in the art will know that there are many established algorithms available to align two sequences. Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith and Waterman, 1981, Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the GCG Wisconsin Software Package), or by visual inspection (see generally Current Protocols in Molecular Biology, F.M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1995 Supplement) (Ausubel)). Examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., 1990, J. Mol. Biol. 215: 403-410 and Altschul et al., 1977, Nucleic Acids Res. 3389-3402, respectively.

[0024] A "reference sequence" refers to a defined sequence used as the basis for sequence comparison. A reference sequence may be a subset of a larger sequence, such as a segment of a full-length gene sequence or polypeptide sequence. Generally, a reference sequence is at least 20 nucleotides or amino acid residues in length, at least 25 residues in length, at least 50 residues in length, or the full length of the nucleic acid or polypeptide. Because two polynucleotides or polypeptides can each contain (1) sequences that are similar between the two sequences (i.e., a portion of the complete sequence), and (2) additional sequences that differ between the two sequences, sequence comparison between two (or more) polynucleotides or polypeptides is typically performed by comparing the sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity.

[0025] A "comparison window" refers to a conceptual segment of at least about 20 contiguous nucleotide positions or amino acid residues, where a sequence can be compared to a reference sequence of at least 20 contiguous nucleotides or amino acids, and the portion of the sequence within the comparison window can contain no more than 20 percent additions or deletions (i.e., gaps) compared to the reference sequence (which does not contain additions or deletions) for optimal alignment of the two sequences. The comparison window can be longer than 20 contiguous residues, including windows of 30, 40, 50, 100, 150, or 200 or more, as appropriate.

[0026] "Substantial identity" refers to a polynucleotide or polypeptide sequence that has at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, or at least 95% sequence identity, more usually at least 98 or 99% sequence identity, compared to a reference sequence over a comparison window that includes at least 90%, 95%, 98%, or 99% of the reference sequence. In a specific embodiment applied to polypeptides, the term "substantial identity" means that two polypeptide sequences share at least 80% sequence identity, preferably at least 89% sequence identity, at least 95% sequence identity, or more (e.g., 99% sequence identity) when optimally aligned, for example, by the programs GAP or BESTFIT using default gap weights. Preferably, residue positions that are not identical differ by conservative amino acid substitutions.

[0027] When reference is made herein to a cellular organism, it should be understood to refer to the organism both in its wild-type state and as a modified organism. Thus, the term yeast includes all wild-type yeasts that occur naturally in nature, as well as any artificial yeasts produced using recombinant techniques.

[0028] The term "yeast" refers to Ascomycota fungi of the class Saccharomycetes, preferably the order Saccharomycetales, preferably the family Saccharomycetaceae. Particularly preferred yeasts belong to the genera Pichia and Saccharomyces, in particular Pichia pastoris and Saccharomyces cerevisiae.

[0029] 3-KCA, or 3-keto-5β-cholanic acid, is represented by the following chemical structure:

[0030] [ka]

[0031] LCA, or lithocholic acid, is represented by the following chemical structure:

[0032] [ka]

[0033] 3-KUDCA, or 7β-hydroxy-3-keto-5β-cholanic acid, is represented by the following chemical structure:

[0034] [ka]

[0035] UDCA, or ursodeoxycholic acid, is represented by the following chemical structure:

[0036] [ka]

[0037] As used herein, carboxylate "salt" refers to a derivative of a compound of the present disclosure in which the parent compound is modified by converting the existing acid moiety into its salt form. Examples of suitable salts include, but are not limited to, alkali salts or organic salts of the acidic residue of the carboxylic acid. The salts of the present invention include conventional non-toxic salts or quaternary ammonium salts of the parent compound, for example, formed from non-toxic inorganic or organic bases. The salts of the present invention can be synthesized from the parent compound containing an acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid form of these compounds with a stoichiometric amount of an appropriate base in water or an organic solvent, or a mixture of the two.

[0038] As used herein, "ester" preferably refers to a -COOR moiety, where R is optionally substituted C1-20 alkyl or optionally substituted aryl.

[0039] As used herein, the term "alkyl" is meant to refer to a saturated hydrocarbon group that is straight-chain or branched. Exemplary alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like. In any of the embodiments or subembodiments of this invention, the alkyl group can contain 1 to about 20, 2 to about 20, 1 to about 10, 1 to about 8, 1 to about 6, 1 to about 4, or 1 to about 3 carbon atoms.

[0040] As used herein, "aryl" refers to monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings) aromatic hydrocarbons (including heteroaromatic hydrocarbons), such as, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, etc. In some embodiments, aryl groups have from 6 to about 20 carbon atoms.

[0041] In any of the embodiments or subembodiments of this invention, optionally substituted moieties include halo, OH, amine, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Hydroxyalkyl, CO(C 1~6 alkyl), CHO, CO2H, CO2(C 1~6 alkyl), and C 1~6 It may alternatively be defined as substituted with 0, 1, 2, or 3 substituents independently selected from haloalkyl.

[0042] As used herein, amide preferably refers to a —C(O)N(R′)(R″) moiety, where R′ and R″ independently represent an optionally substituted C 1~20 Alternatively, the carboxylamide of UDCA can be tauroursodeoxycholic acid ("TUDCA").

[0043] The "P450 7β-hydroxylase system" of the present invention refers to a Class II CYP enzyme system capable of hydroxylating the 7-H position of LCA or K-LCA. As discussed in Durairaj et al. Microb Cell Fact (2016) 15:125, the Class II CYP enzyme system includes two integral membrane proteins containing the cofactors FAD and FMN: P450 7β-hydroxylase (sometimes referred to herein as "CYP") and cytochrome P450 reductase (sometimes referred to herein as "CPR"), which transfer two electrons from NAD(P)H to the heme moiety. The system also includes a third protein component, Cyt b5, which transfers the second electron to the oxyferous CYP.

[0044] Discussion of the Main Embodiments A first principal embodiment of the present invention provides a method for converting LCA or 3-KCA, or their carboxylic acid ester, carboxylamide or carboxylate salt, to UDCA or 3-KUDCA, or their carboxylic acid ester, carboxylamide or carboxylate salt, comprising contacting LCA or 3-KCA, or their carboxylic acid ester, carboxylamide or carboxylate salt, with a 7β-hydroxylase system in the presence of yeast, or an extract or lysate thereof, wherein the 7β-hydroxylase system is not native to the yeast.

[0045] A second main embodiment provides a plasmid comprising a nucleic acid sequence selected from SEQ ID NO:8; SEQ ID NO:11; SEQ ID NO:14; SEQ ID NO:17; SEQ ID NO:20; SEQ ID NO:23; SEQ ID NO:26; SEQ ID NO:29; or SEQ ID NO:32; or a nucleic acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the foregoing sequences.

[0046] The third main embodiment provides an organism transformed with a CYP-encoding nucleic acid sequence selected from SEQ ID NO:8; SEQ ID NO:11; SEQ ID NO:14; SEQ ID NO:17; SEQ ID NO:20; SEQ ID NO:23; SEQ ID NO:26; SEQ ID NO:29; and SEQ ID NO:32; or a nucleic acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the foregoing nucleic acid sequences.

[0047] In a fourth main embodiment, the present invention provides a reaction mixture comprising (i) LCA or 3-KCA, (ii) yeast, or an extract or lysate thereof, and (iii) a 7β-hydroxylation system.

[0048] A fifth principal embodiment provides a reaction mixture comprising yeast and a 7β-hydroxylation system comprising a P450 oxidoreductase ("CPR") enzyme and a P450 7β-hydroxylase ("CYP") enzyme, where the CYP enzyme is an enzyme native to Gibberella zeae, preferably Gibberella zeae PH1 or Gibberella zeae VKM2600, most preferably Gibberella zeae VKM2600.

[0049] Subembodiment Discussion As noted above, the present invention is preferably practiced in the presence of yeast transformed to express a non-native 7β-hydroxylation system, preferably selected from the genera Saccharomyces and Pichia, and most preferably selected from Saccharomyces cerevisiae and Pichia pastoris.

[0050] The organisms used in the methods of the invention will be transformed with a non-native 7β-hydroxylation system comprising a non-native P450 7β-hydroxylase ("CYP") enzyme and, optionally, a non-native P450 oxidoreductase ("CPR") enzyme. While the CPR enzyme is critical to the 7β-hydroxylase system, it is not absolutely necessary that the CPR enzyme be foreign to the organism, such that a native, endogenous enzyme may be sufficient for yeast.

[0051] Preferred CYP enzymes for practicing the present invention are encoded by a CYP-encoding nucleic acid sequence selected from SEQ ID NO:8; SEQ ID NO:11; SEQ ID NO:14; SEQ ID NO:17; SEQ ID NO:20; SEQ ID NO:23; SEQ ID NO:26; SEQ ID NO:29; and SEQ ID NO:32; or a nucleic acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the foregoing nucleic acid sequences.

[0052] Nucleic acids encoding CYPs can be selected from any one of the foregoing SEQ ID NOs or combinations thereof and combined with any of the CPR enzymes of the present invention. In one embodiment, the encoding nucleic acid sequence is selected from SEQ ID NO:8; SEQ ID NO:11; SEQ ID NO:14; SEQ ID NO:17; and SEQ ID NO:20; or a nucleic acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to any of the foregoing sequences. In another embodiment, the nucleic acid is selected from SEQ ID NO:23; SEQ ID NO:26; or SEQ ID NO:29; or a nucleic acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to any of the foregoing sequences. In yet another embodiment, the nucleic acid sequence is SEQ ID NO:32; or a nucleic acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to SEQ ID NO:32. is selected from.

[0053] The CYP enzyme preferably comprises a CYP amino acid sequence selected from SEQ ID NO:9; SEQ ID NO:12; SEQ ID NO:15; SEQ ID NO:18; SEQ ID NO:21; SEQ ID NO:24; SEQ ID NO:27; SEQ ID NO:30; or SEQ ID NO:33; or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the foregoing amino acid sequences.

[0054] The CYP enzyme can be selected from any one of the foregoing SEQ ID NOs, or a combination thereof, and combined with any of the CPR enzymes of the present invention. In one embodiment, the CYP enzyme comprises SEQ ID NO:9; SEQ ID NO:12; SEQ ID NO:15; SEQ ID NO:18; and SEQ ID NO:21; or an amino acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to any of the foregoing sequences. In another embodiment, the CYP enzyme comprises SEQ ID NO:24; SEQ ID NO:27; or SEQ ID NO:30; or an amino acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to any of the foregoing sequences. In yet another embodiment, the CYP enzyme comprises SEQ ID NO:33; or an amino acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to SEQ ID NO:33.

[0055] Preferred plasmids encoding CYP enzymes of the present invention preferably comprise a nucleic acid sequence selected from SEQ ID NO:7; SEQ ID NO:10; SEQ ID NO:13; SEQ ID NO:16; SEQ ID NO:19; SEQ ID NO:22; SEQ ID NO:25; SEQ ID NO:28; or SEQ ID NO:31; or a nucleic acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the foregoing nucleic acid sequences.

[0056] In one embodiment, the plasmid encoding the CYP enzyme comprises SEQ ID NO:7; SEQ ID NO:10; SEQ ID NO:13; SEQ ID NO:16; or SEQ ID NO:19; or a nucleic acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to any of the foregoing sequences. In another embodiment, the plasmid encoding the CYP enzyme comprises SEQ ID NO:22; SEQ ID NO:25; or SEQ ID NO:28; or a nucleic acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to any of the foregoing sequences. In yet another embodiment, the plasmid encoding the CYP enzyme comprises SEQ ID NO:31; or a nucleic acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to SEQ ID NO:31.

[0057] In one embodiment, the CYP enzyme is a protein native to Gibberella zeae, preferably Gibberella zeae PH1 or Gibberella zeae VKM2600, most preferably Gibberella zeae VKM2600, and the organism is transformed to express such a protein.

[0058] The CPR enzyme in the 7β-hydroxylation system may be native to the organism in which the 7β-hydroxylase activity is expressed and may be encoded by a CPR-encoding nucleic acid sequence selected from SEQ ID NO: 2 and SEQ ID NO: 5, or a nucleic acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to any of the foregoing nucleic acid sequences. The CPR enzyme preferably comprises a CPR amino acid sequence selected from SEQ ID NO: 3 and SEQ ID NO: 6, or an amino acid sequence having at least 85%, 90%, 95%, 98%, or 99% identity to any of the foregoing amino acid sequences.

[0059] In one embodiment, the method of the present invention is carried out by contacting LCA, or its carboxylic acid ester, carboxylamide, or carboxylate salt, with a 7β-hydroxylase system to produce UDCA, or its carboxylic acid ester, carboxylamide, or carboxylate salt. In another embodiment, the method of the present invention is carried out by contacting 3-KCA, or its carboxylic acid ester, carboxylamide, or carboxylate salt, with a 7β-hydroxylase system to produce 3-KUDCA, or its carboxylic acid ester, carboxylamide, or carboxylate salt. When producing 3-KUDCA, or its carboxylic acid ester, carboxylamide, or carboxylate salt, the method of the present invention optionally further comprises reducing 3-KUDCA, or its carboxylic acid ester, carboxylamide, or carboxylate salt, to UDCA, or its carboxylic acid ester, carboxylamide, or carboxylate salt.

[0060] In a preferred embodiment, the method of the present invention further comprises a step of isolating UDCA or 3-KUDCA, or their carboxylic acid ester, carboxylamide, or carboxylate salt, from the 7β-hydroxylase system. By isolated, we mean that the UDCA or 3-KUDCA is substantially pure from the 7β-hydroxylase system and the reaction mixture in which it was produced. Thus, when considering the weight of any remaining reaction mixture, the UDCA or 3-KUDCA is at least 90% pure, at least 95% pure, or at least 98% pure. In a particularly preferred embodiment, the UDCA or 3-KUDCA, or their carboxylic acid ester, carboxylamide, or carboxylate salt, is produced as a substantially pure diastereoisomer. "Substantially pure diastereomer" refers to a diastereomer that is at least 90% pure, at least 95% pure, or at least 98% pure when considering its 7α-diastereomer.

[0061] Engineered CYP and CPR enzymes CYP and CPR enzymes with properties different from the CYP and CPR enzyme sequences disclosed herein can be obtained by mutating the genetic material encoding the CYP or CPR enzyme and identifying a polynucleotide that expresses an engineered enzyme with the desired properties. These non-naturally occurring CYP and CPR enzymes can be created by a variety of well-known techniques, such as in vitro mutagenesis or directed evolution. In some embodiments, directed evolution is an attractive method for creating engineered enzymes because of the relative ease of generating mutations throughout a polypeptide-encoding gene and the ability to retrieve previously mutated polynucleotides and subject them to additional cycles of mutagenesis and / or recombination to obtain further improvements in selected enzyme properties. Subjecting the entire gene to mutagenesis can reduce bias that can result from restricting changes to limited regions of the gene. Subjecting the entire gene to mutagenesis can also enhance the creation of enzymes affected in various enzyme properties, since widely spaced portions of the enzyme may play roles in different aspects of enzyme function.

[0062] In mutagenesis and directed evolution, a parent or reference polynucleotide encoding a naturally occurring or wild-type CYP or CPR enzyme is subjected to a mutagenesis process, such as random mutagenesis and recombination, to introduce mutations into the polynucleotide. The mutated polynucleotide is expressed and translated, thereby producing an engineered CYP or CPR enzyme containing modifications to the polypeptide. As used herein, "modification" includes amino acid substitution, deletion, and insertion. Any one or a combination of modifications can be introduced into a naturally occurring enzymatically active polypeptide to produce an engineered enzyme, which can then be screened by various methods to identify a polypeptide and corresponding polynucleotide with the desired improvement in specific enzyme properties.

[0063] 7-beta-hydroxylase environment CYP and CPR enzymes can be present intracellularly, in cell culture medium, on an immobilized substrate, or in other forms, such as lysates and extracts of cells recombinantly engineered to express the enzymes, or isolated preparations. The term "isolated polypeptide" refers to a polypeptide that has been substantially separated from other contaminants that naturally accompany it, such as proteins, lipids, and polynucleotides. The term encompasses polypeptides that have been removed or purified from their naturally occurring environment or expression system (e.g., host cells or in vitro synthesis).

[0064] In some embodiments, the isolated CYP and CPR enzymes are present in a substantially pure polypeptide composition. The term "substantially pure polypeptide" refers to a composition in which the polypeptide species is the predominant species present (i.e., the polypeptide species is more abundant than any other individual macromolecular species in the composition, on a molar or weight basis), and a "substantially pure polypeptide" is a substantially purified composition overall when the species constitutes at least about 50 percent of the macromolecular species present, on a molar or weight percent basis. Overall, a substantially pure CYP and CPR enzyme composition will constitute about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 95% or more, or about 98% or more of all macromolecular species present in the composition, on a molar or weight percent basis. In some embodiments, the species of interest is purified to essential homogeneity (i.e., contaminant species are not detectable in the composition by conventional detection methods), in which case the composition consists essentially of only CYP and CPR macromolecular species. Solvent species, small molecules (<500 Daltons) and elemental ion species are not considered macromolecular species.

[0065] Coding polynucleotide Isolated polynucleotides encoding CYP and CPR enzymes can be manipulated in a variety of ways to result in expression of the enzymes. Manipulation of the isolated polynucleotide prior to its insertion into a vector may be desirable or necessary, depending on the expression vector. Techniques for modifying polynucleotide and nucleic acid sequences utilizing recombinant DNA methods are well known in the art. Guidance is provided in Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory Press; and Current Protocols in Molecular Biology, Ausubel, F. ed., Greene Pub. Associates, 1998, updated to 2006.

[0066] Thus, in another aspect, the present disclosure is also directed to recombinant expression vectors that, depending on the type of host into which they will be introduced, include a polynucleotide encoding a CYP enzyme or CPR enzyme polypeptide or variant thereof, and one or more expression control regions, such as a promoter and terminator, an origin of replication, etc. Various nucleic acid sequences and control sequences can be ligated together to create recombinant expression vectors that can contain one or more convenient restriction sites, resulting in the insertion or substitution of a nucleic acid sequence encoding a polypeptide at such sites. In creating such recombinant expression vectors, a coding sequence is placed within the vector so that it is operably linked to the appropriate control sequences for expression.

[0067] The recombinant expression vector can be any vector (e.g., a plasmid or virus) that can be suitably subjected to recombinant DNA procedures and can bring about the expression of a polynucleotide sequence. The choice of vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vector can be a linear or a closed circular plasmid.

[0068] The expression vector can be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity whose replication is independent of chromosomal replication, such as a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector can contain any means for ensuring self-replication. Alternatively, the vector can be integrated into the genome when introduced into a host cell and replicated together with the chromosome into which it is integrated. Furthermore, a single vector or plasmid, or two or more vectors or plasmids that together contain the entire DNA to be introduced into the genome of the host cell, can be used. In a particularly preferred embodiment, the plasmid or vector of the present invention is under the control of the AOX1 promoter and AOX1 terminator sequence.

[0069] The term "control sequence" is defined herein to include all components necessary or beneficial for expression of a polypeptide of the present disclosure. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a minimum, control sequences include a promoter, transcriptional and translational stop signals, and a ribosome binding site (to terminate translation). Linkers may be provided in the control sequences for the purpose of introducing specific restriction sites to facilitate ligation of the control sequences with the coding region of the nucleic acid sequence encoding the polypeptide.

[0070] The term "operably linked" is defined herein as a configuration in which a control sequence is appropriately positioned relative to the coding sequence of a DNA sequence so as to direct expression of a polynucleotide and / or polypeptide. The control sequence may be a suitable promoter sequence. A "promoter sequence" is a nucleic acid sequence recognized by a host cell for expression of a coding region. The promoter sequence contains transcriptional control sequences that mediate expression of the polypeptide. The promoter may be any nucleic acid sequence that shows transcriptional activity in the host cell of choice, including mutant, truncated, and hybrid promoters, and may be derived from a gene encoding an extracellular or intracellular polypeptide that is either homologous or heterologous to the host cell.

[0071] The control sequence may also be a suitable transcription terminator sequence, i.e., a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' end of the nucleic acid sequence encoding the polypeptide. Any terminator that is functional in the host cell of choice can be used in the present invention.

[0072] Host Cells for Expression of CYP and CPR Polypeptides In another aspect, the present disclosure provides a host cell comprising a polynucleotide encoding the CYP and CPR enzymes of the present disclosure, the polynucleotide being operably linked to one or more control sequences for expression of the CYP and CPR enzymes in the host cell. Host cells for use in expressing the CYP and CPR enzymes encoded by the expression vectors of the present invention are well known in the art and include, in particular, yeast cells of the present invention (e.g., Saccharomyces cerevisiae or Pichia pastoris). In a specific embodiment, the method of the present invention is carried out using whole cells expressing the CYP and CPR enzymes, or extracts or lysates of such cells, where the whole cells or extracts or lysates of such whole cells are selected from Pichia pastoris and Saccharomyces cerevisiae. Suitable culture media and growth conditions for the above host cells are well known in the art.

[0073] The polynucleotide for expressing CYP enzyme and CPR enzyme can be introduced into cells by various methods known in the art.For yeast as described herein, typical methods are transformation (for example, electroporation or calcium chloride mediated) or conjugation, or in some cases by protoplast fusion.Various methods for introducing polynucleotide into cells will be clear to those skilled in the art.

[0074] Reaction conditions When carrying out the stereoselective hydroxylation described herein, the CYP and CPR enzymes can be added to the reaction mixture in the form of purified enzymes (including immobilized variants), whole cells transformed with the genes encoding the enzymes, and / or cell extracts and / or lysates of such cells. The genes encoding the engineered CYP and CPR enzymes can be transformed into host cells separately or together into the same host cell.

[0075] For example, in some embodiments, one set of host cells may be transformed with genes encoding CYP enzymes, and another set may be transformed with genes encoding CPR enzymes. Both sets of transformed cells may be utilized together in a reaction mixture, either in the form of whole cells or in the form of lysates or extracts derived therefrom. In other embodiments, host cells may be transformed with genes encoding both engineered CYP and CPR enzymes.

[0076] Whole cells transformed with genes encoding CYP and CPR enzymes, or cell extracts and / or lysates thereof, can be used in a variety of different forms, including solid (e.g., lyophilized, spray-dried, immobilized, etc.) or semi-solid (e.g., crude paste). Cell extracts or lysates can be partially purified by precipitation (ammonium sulfate, polyethyleneimine, heat treatment, etc.) followed by a desalting procedure (e.g., ultrafiltration, dialysis, etc.) before lyophilization.

[0077] The total amount of reactants used in the hydroxylation reaction will vary depending on the amount of substrate for the CYP and CPR enzymes used. The following guidelines can be used to determine the amount of CYP and CPR enzymes to use. Generally, the sterol substrate is used at a concentration of about 1 to 20 grams / liter, using about 50 mg / liter to about 5 g / liter of hydroxylase system. The weight ratio of sterol to hydroxylase system in the reaction mixture is usually about 10:1 to 200:1. Those skilled in the art will readily understand how to vary these amounts to match the desired productivity level and production scale.

[0078] The order of addition of reactants is not important. The reactants may be added together to the solvent at the same time (e.g., a single-phase solvent, a two-phase aqueous co-solvent system, etc.), or alternatively, some of the reactants may be added separately and some may be added together at different times. For example, the hydroxylase system may be added to the solvent first. Preferably, however, the enzyme preparation is added last.

[0079] Suitable conditions for carrying out the CYP and CPR enzyme-catalyzed reactions described herein include a wide range of conditions, including contacting the CYP and CPR enzymes with a sterol substrate at an empirical pH and temperature, and detecting the product using, for example, the methods described in the Examples provided herein.

[0080] The hydroxylase-catalyzed reactions described herein are carried out entirely in a solvent. Water is most preferred, but organic solvents such as ethyl acetate, butyl acetate, 1-octanol, heptane, octane, methyl t-butyl ether (MTBE), toluene, and ionic liquids such as 1-ethyl-4-methylimidazolium tetrafluoroborate, 1-butyl-3-methylimidazolium tetrafluoroborate, and 1-butyl-3-methylimidazolium hexafluorophosphate can be used alone or in combination with water in certain circumstances. In a preferred embodiment, an aqueous solvent is used, including water and aqueous co-solvent systems. The solvent system is preferably greater than 50%, 75%, 90%, 95%, or 98% water, and in one embodiment is 100% water.

[0081] During the hydroxylation process, the pH of the reaction mixture may change. The pH of the reaction mixture can be maintained at a desired pH or within a desired pH range by adding an acid or base during the reaction. Alternatively, the pH can be controlled by using a solvent containing a buffer. Suitable buffers for maintaining a desired pH range are known in the art, and include, for example, phosphate buffers, triethanolamine buffers, etc. A combination of a buffer and the addition of an acid or base can also be used.

[0082] The hydroxylation is typically carried out at a temperature ranging from about 15° C. to about 75° C. In some embodiments, the reaction is carried out at a temperature ranging from about 20° C. to about 55° C. In yet other embodiments, the reaction is carried out at a temperature ranging from about 20° C. to about 45° C. The reaction may be carried out under room temperature conditions.

[0083] The reaction as a whole may be allowed to proceed until essentially complete or nearly complete hydroxylation of the substrate is obtained. Hydroxylation of the substrate to the product can be monitored using known methods by detecting the substrate and / or the product. Suitable methods include gas chromatography, HPLC, and the like. The overall conversion yield of the sterol hydroxylation product produced in the reaction mixture is greater than about 50%, sometimes greater than about 60%, sometimes greater than about 70%, sometimes greater than about 80%, sometimes greater than about 90%, and sometimes even greater than about 97%.

[0084] The hydroxylated product can be recovered from the reaction mixture and, if necessary, further purified using methods known to those skilled in the art. Chromatographic techniques for isolation from hydroxylase systems include, among others, reverse-phase chromatography, high-performance liquid chromatography, ion-exchange chromatography, gel electrophoresis, and affinity chromatography. The conditions for purifying a particular sterol will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity, molecular weight, molecular shape, etc., and will be apparent to those skilled in the art. A preferred method for product purification involves extraction into an organic solvent followed by crystallization. [Example]

[0085] In the following examples, efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperatures, etc.), but some errors and deviations should be accounted for. The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention.

[0086] General Methods for Examples 1-15 DNA isolation, handling, and manipulation are performed using standard methods (Green and Sambrook, 2012), including restriction enzyme digestion, PCR, cloning techniques, and bacterial cell transformation. See, e.g., Green, MR, Sambrook, J., 2012. Molecular Cloning: A Laboratory Manual, Fourth Edition, 4 Lab edition. ed. Cold Spring Harbor Press, Cold Spring Harbor, NY.

[0087] Synthetic DNA is ordered from commercial vendors such as Eurofins Scientific SE (Brussels, Belgium), Integrated DNA Technologies (Coralville, Iowa), Genewiz (a Brooks Life Sciences Company) (South Plainfield, New Jersey), or Twist Bioscience (San Francisco, California). Genes are supplied in custom vectors as described in the Examples.

[0088] Culture medium 2TY medium contains 16 g / L bactotryptone, 10 g / L yeast extract, and 5 g / L NaCl, and is sterilized by autoclaving. 2TY agar also contains 15 g / L agar.

[0089] YPD medium contains 10 g / L yeast extract and 10 g / L bactotryptone and is sterilized by autoclaving. 50 ml / L of sterile 40% glucose stock solution is added immediately before use. YPD agar plates also contain 15 g / L agar.

[0090] BMG contains 100 mM potassium phosphate, pH 7.5, YNB 13.4 g / L, biotin 0.4 mg / L, and 1% glycerol.

[0091] BMM contains 100 mM potassium phosphate, pH 7.5, YNB 13.4 g / L, biotin 0.4 mg / L, and 1% methanol.

[0092] BMMY medium is made by dissolving 10 g of yeast extract and 10 g of Bactotryptone in 700 ml of dH2O and sterilizing by autoclaving. Immediately before use, add 100 ml of YNB stock solution, 2 ml of biotin stock solution, and 100 ml of 100 mM potassium phosphate buffer, pH 6.0.

[0093] The YNB stock solution is composed of 134 g / L of yeast nitrogen base containing ammonium sulfate and not containing amino acids, and is sterilized by autoclaving.

[0094] Biotin stock solution consists of 200 mg / L biotin and is filter sterilized using a 0.2 μm filter.

[0095] material Restriction enzymes are purchased from New England Biolabs (Ipswich, Massachusetts) or Promega Corporation (Madison, Wisconsin). Media components, chemicals, and PCR primers are obtained from MilliporeSigma (St. Louis, Missouri). Zeocin is supplied by Thermo Fisher Scientific (Waltham, Massachusetts).

[0096] Transformation of Pichia Pastoris Pichia pastoris (Komagataella phaffi NRRL Y-11430 / ATCC 76273, hereafter referred to as Pichia pastoris SAND101) is grown overnight in 10 ml of YPD at 30°C with shaking at 250 RPM. This culture is used to inoculate 500 ml of YPD to an OD600 of 0.1, then incubated at 30°C with shaking at 250 RPM until an OD600 of 1.3-1.5 is reached. Cells are harvested by centrifugation at 2000 x g for 10 minutes at 4°C and resuspended in 100 ml of YPD supplemented with 20 ml of 1 M HEPES, pH 8.0, and 2.5 ml of 1 M DTT. Cells are incubated at 30°C for 15 minutes without shaking. Add cold dH2O to a final volume of 500 ml and collect the cells by centrifugation at 2000 x g for 10 minutes at 4°C. Wash the cells with 250 ml of cold dH2O and collect them by centrifugation at 2000 x g for 10 minutes at 4°C. Wash the cells with 20 ml of cold 1 M sorbitol and collect them by centrifugation at 2000 x g for 10 minutes at 4°C. Resuspend the cells in 500 μl of cold 1 M sorbitol. Add 100 ng of DNA to 40 μl of competent cells and transfer to a 2 mm gap electroporation cuvette pre-chilled on ice. Electroporate the cells in a BTRX ECM 630 decaying wave electroporation system using settings of 1500 V, 200 Ω, and 25 μF. Immediately add 1 ml of cold 1 M sorbitol and transfer the mixture to a sterile Eppendorf tube. Allow the cells to regenerate for at least 30 minutes at 30°C with shaking at 250 RPM. The cells are then spread onto YPD agar plates containing the appropriate antibiotics and then incubated at 30° C. for 2 days or until colonies are visible.

[0097] [Example 1] Construction of a Pichia pastoris strain capable of expressing SEQ ID NO:2 (FGSG_04903) Plasmid pSAND102 is obtained from a commercial provider as synthetic DNA having the sequence of SEQ ID NO: 1. Briefly, this plasmid contains the AOX1 promoter sequence followed by a gene having the sequence of SEQ ID NO: 2, encoding a P450 reductase under the control of the AOX1 promoter and having the sequence of SEQ ID NO: 3, followed by the AOX1 terminator sequence. The AOX1 promoter contains a unique PmeI restriction site, allowing linearization of plasmid pSAND102.

[0098] Plasmid pSAND102 is linearized with the restriction enzyme PmeI. The linearized plasmid is purified from the reaction mixture using, for example, a commercially available column purification kit. Electrocompetent cells of Pichia pastoris strain SAND101 are transformed with the PmeI-linearized plasmid pSAND102, allowing it to be integrated into the genome at the AOX1 promoter. Transformants are plated onto YPD agar containing 100 μg / ml nourseothricin and incubated at 30°C until colonies are visible. The resulting strain is designated Pichia pastoris SAND102.

[0099] [Example 2] Construction of a Pichia pastoris strain capable of expressing SEQ ID NO:5 (FGSG_03175) Plasmid pSAND103 is obtained from a commercial provider as synthetic DNA having the sequence of SEQ ID NO: 4. Briefly, this plasmid contains the AOX1 promoter sequence followed by a gene having the sequence of SEQ ID NO: 5, encoding a P450 reductase under the control of the AOX1 promoter and having the sequence of SEQ ID NO: 6, followed by the AOX1 terminator sequence. The AOX1 promoter contains a unique PmeI restriction site, allowing linearization of plasmid pSAND103.

[0100] Plasmid pSAND103 is linearized with the restriction enzyme PmeI. The linearized plasmid is purified from the reaction mixture using, for example, a commercially available column purification kit. Electrocompetent cells of Pichia pastoris strain SAND101 are transformed with the PmeI-linearized plasmid pSAND103, allowing it to be integrated into the genome at the AOX1 promoter. Transformants are plated onto YPD agar containing 100 μg / ml nourseothricin and incubated at 30°C until colonies are visible. The resulting strain is designated Pichia pastoris SAND103.

[0101] [Example 3] Construction of a Pichia pastoris strain capable of expressing SEQ ID NO:8 (FGSG_05333) Plasmid pSAND104 is obtained from a commercial provider as synthetic DNA with the sequence of SEQ ID NO: 7. Briefly, this plasmid contains the AOX1 promoter sequence followed by a gene with the sequence of SEQ ID NO: 8, encoding a P450 under the control of the AOX1 promoter with the sequence of SEQ ID NO: 9, followed by the AOX1 terminator sequence.

[0102] Electrocompetent cells of Pichia pastoris strain SAND102 were transformed with plasmid pSAND104, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND104.

[0103] Electrocompetent cells of Pichia pastoris strain SAND103 were transformed with plasmid pSAND104, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND105.

[0104] [Example 4] Construction of a Pichia pastoris strain capable of expressing SEQ ID NO: 11 (FGSG_02672) Plasmid pSAND105 is obtained from a commercial provider as synthetic DNA with the sequence of SEQ ID NO: 10. Briefly, this plasmid contains the AOX1 promoter sequence followed by a gene with the sequence of SEQ ID NO: 11, encoding a P450 under the control of the AOX1 promoter with the sequence of SEQ ID NO: 12, followed by the AOX1 terminator sequence.

[0105] Electrocompetent cells of Pichia pastoris strain SAND102 were transformed with plasmid pSAND105, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND106.

[0106] Electrocompetent cells of Pichia pastoris strain SAND103 were transformed with plasmid pSAND105, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND107.

[0107] [Example 5] Construction of a Pichia pastoris strain capable of expressing SEQ ID NO: 14 (FGSG_10695) Plasmid pSAND106 is obtained from a commercial provider as synthetic DNA with the sequence of SEQ ID NO: 13. Briefly, this plasmid contains the AOX1 promoter sequence followed by a gene with the sequence of SEQ ID NO: 14, encoding a P450 under the control of the AOX1 promoter with the sequence of SEQ ID NO: 15, followed by the AOX1 terminator sequence.

[0108] Electrocompetent cells of Pichia pastoris strain SAND102 were transformed with plasmid pSAND106, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND108.

[0109] Electrocompetent cells of Pichia pastoris strain SAND103 were transformed with plasmid pSAND106, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND109.

[0110] [Example 6] Construction of a Pichia pastoris strain capable of expressing SEQ ID NO: 17 (P450 51(1)-FGSG_04092) Plasmid pSAND107 is obtained from a commercial provider as synthetic DNA with the sequence of SEQ ID NO: 16. Briefly, this plasmid contains the AOX1 promoter sequence followed by a gene with the sequence of SEQ ID NO: 17, encoding a P450 under the control of the AOX1 promoter with the sequence of SEQ ID NO: 18, followed by the AOX1 terminator sequence.

[0111] Electrocompetent cells of Pichia pastoris strain SAND102 were transformed with plasmid pSAND107, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND110.

[0112] Electrocompetent cells of Pichia pastoris strain SAND103 were transformed with plasmid pSAND107, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND111.

[0113] [Example 7] Construction of a Pichia pastoris strain capable of expressing SEQ ID NO: 20 (P450 51(2)-FGSG_01000) Plasmid pSAND108 is obtained from a commercial provider as synthetic DNA with the sequence of SEQ ID NO: 19. Briefly, this plasmid contains the AOX1 promoter sequence followed by a gene with the sequence of SEQ ID NO: 20, encoding a P450 under the control of the AOX1 promoter with the sequence of SEQ ID NO: 21, followed by the AOX1 terminator sequence.

[0114] Electrocompetent cells of Pichia pastoris strain SAND102 were transformed with plasmid pSAND108, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND112.

[0115] Electrocompetent cells of Pichia pastoris strain SAND103 were transformed with plasmid pSAND108, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND113.

[0116] [Example 8] Construction of a Pichia pastoris strain capable of expressing SEQ ID NO: 23 (FGRAMPH1_01T05089) Plasmid pSAND109 is obtained from a commercial provider as synthetic DNA with the sequence of SEQ ID NO: 22. Briefly, this plasmid contains the AOX1 promoter sequence followed by a gene with the sequence of SEQ ID NO: 23, encoding a P450 under the control of the AOX1 promoter with the sequence of SEQ ID NO: 24, followed by the AOX1 terminator sequence.

[0117] Electrocompetent cells of Pichia pastoris strain SAND102 were transformed with plasmid pSAND109, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND114.

[0118] Electrocompetent cells of Pichia pastoris strain SAND103 were transformed with plasmid pSAND109, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND115.

[0119] [Example 9] Construction of a Pichia pastoris strain capable of expressing SEQ ID NO: 26 (FGRAMPH1_01T09325) Plasmid pSAND110 is obtained from a commercial provider as synthetic DNA with the sequence of SEQ ID NO: 25. Briefly, this plasmid contains the AOX1 promoter sequence followed by a gene with the sequence of SEQ ID NO: 26, encoding a P450 under the control of the AOX1 promoter with the sequence of SEQ ID NO: 27, followed by the AOX1 terminator sequence.

[0120] Electrocompetent cells of Pichia pastoris strain SAND102 were transformed with plasmid pSAND110, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND116.

[0121] Electrocompetent cells of Pichia pastoris strain SAND103 were transformed with plasmid pSAND110, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND117.

[0122] [Example 10] Construction of a Pichia pastoris strain capable of expressing SEQ ID NO: 29 (FGRAMPH1_01T21239) Plasmid pSAND111 is obtained from a commercial provider as synthetic DNA with the sequence of SEQ ID NO: 28. Briefly, this plasmid contains the AOX1 promoter sequence followed by a gene with the sequence of SEQ ID NO: 29, encoding a P450 under the control of the AOX1 promoter with the sequence of SEQ ID NO: 30, followed by the AOX1 terminator sequence.

[0123] Electrocompetent cells of Pichia pastoris strain SAND102 were transformed with plasmid pSAND111, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND118.

[0124] Electrocompetent cells of Pichia pastoris strain SAND103 were transformed with plasmid pSAND111, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND119.

[0125] [Example 11] Construction of a Pichia pastoris strain capable of expressing SEQ ID NO: 32 (FGSG_02672V2) Plasmid pSAND112 is obtained from a commercial provider as synthetic DNA with the sequence of SEQ ID NO: 31. Briefly, this plasmid contains the AOX1 promoter sequence followed by a gene with the sequence of SEQ ID NO: 32, encoding a P450 under the control of the AOX1 promoter with the sequence of SEQ ID NO: 33, followed by the AOX1 terminator sequence.

[0126] Electrocompetent cells of Pichia pastoris strain SAND102 were transformed with plasmid pSAND112, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND120.

[0127] Electrocompetent cells of Pichia pastoris strain SAND103 were transformed with plasmid pSAND112, plated onto YPD agar containing 100 μg / ml nourseothricin and 100 μg / ml zeocin, and incubated at 30°C until colonies were visible. The resulting strain was designated Pichia pastoris SAND121.

[0128] [Example 12] Expression of P450 genes and P450 reductase genes in Pichia pastoris strains Pichia pastoris SAND104 to Pichia pastoris SAND121 Pichia pastoris SAND104, Pichia pastoris SAND105, Pichia pastoris SAND106, Pichia pastoris SAND107, Pichia pastoris SAND108, Pichia pastoris SAND109, Pichia pastoris SAND110, Pichia pastoris SAND111, Pichia pastoris SAND112, Pichia pastoris SAND113, Pichia pastoris SAND114, Pichia pastoris Conversion of lithocholic acid to ursodeoxycholic acid by strains Pichia pastoris SAND115, Pichia pastoris SAND116, Pichia pastoris SAND117, Pichia pastoris SAND118, Pichia pastoris SAND119, Pichia pastoris SAND120, and Pichia pastoris SAND121 is tested by induction of gene expression using standard methods. In one such method, YPD medium containing 100 μg / ml nourseothricin and 100 μg / ml zeocin is inoculated with a fresh single colony of the strain and incubated overnight at 30°C with shaking at 250 RPM. Inoculate 1 / 10 volume of the overnight culture into fresh BMMY medium containing 2 mM aminolevulinic acid, nourseothricin 100 μl / ml, and zeocin 100 μg / ml and incubate at 30 °C with shaking at 250 RPM until an OD600 of 1.0 is reached. Add methanol to a final concentration of 0.5% (v / v) and lithocholic acid to a final concentration of 1 mM and resume incubation at 30 °C with shaking at 250 RPM for 2-3 days.

[0129] Products, including UDCA, are extracted from the broth using standard methods, such as those described in X. Ma and X. Cao, Bioresources and Bioprocessing volume 1, Article number: 5 (2014) and F. Tonin and I. Arends, Beilstein J Org Chem. 2018; 14: 470-483. In one method, the culture is extracted into an equal volume of ethyl acetate, the pH is adjusted to less than 4 by adding acid, the ethyl acetate phase is separated, the solvent is then removed by evaporation, and the desired sterol is then purified using chromatography.

[0130] [Example 13] LCA conversion using whole cells of Pichia pastoris strains Pichia pastoris SAND104 to Pichia pastoris SAND121 grown in BMG medium Pichia pastoris SAND104, Pichia pastoris SAND105, Pichia pastoris SAND106, Pichia pastoris SAND107, Pichia pastoris SAND108, Pichia pastoris SAND109, Pichia pastoris SAND110, Pichia pastoris SAND111, Pichia pastoris SAND112, Pichia pastoris SAND113, Pichia pastoris SAND114, Pichia pastoris Conversion of lithocholic acid to ursodeoxycholic acid by strains Pichia pastoris SAND115, Pichia pastoris SAND116, Pichia pastoris SAND117, Pichia pastoris SAND118, Pichia pastoris SAND119, Pichia pastoris SAND120, and Pichia pastoris SAND121 is tested by induction of gene expression using standard methods, such as those described in W. Lu, J. Feng, X. Chen, et al., 2019 Appl. Environ. Microbiol. 85, e01182-19. In this method, 25 ml of BMG medium is inoculated with a fresh single colony of the strain and incubated at 30°C with shaking at 250 RPM to an OD600 of 10. Cells are harvested by centrifugation at 4000 x g for 5 minutes and suspended in BMM medium containing 2 mM aminolevulenic acid to an OD600 of 1.0. The culture is incubated at 20°C with shaking at 250 RPM for 5 days with the addition of methanol (1% v / v) every 24 hours.

[0131] The cells are harvested by centrifugation at 4000 x g for 5 minutes and resuspended in 30 ml of 50 mM potassium phosphate buffer, pH 7.5, containing 2 mM aminolevulinic acid and 1 mM lithocholic acid. The cell suspension is incubated at 30°C for 3 days with shaking at 200 RPM, with the addition of methanol (1% v / v) every 24 hours.

[0132] Products, including UDCA, are extracted from the broth using standard methods, such as those described in X. Ma and X. Cao, Bioresources and Bioprocessing volume 1, Article number: 5 (2014) and F. Tonin and I. Arends, Beilstein J Org Chem. 2018; 14: 470-483. In one method, the culture is extracted into an equal volume of ethyl acetate, the pH is adjusted to less than 4 by adding acid, the ethyl acetate phase is separated, the solvent is then removed by evaporation, and the desired sterol is then purified using chromatography.

[0133] [Example 14] 3-KCA transformation using whole cells of Pichia pastoris strains Pichia pastoris SAND104 to Pichia pastoris SAND121 grown in YPD medium Pichia pastoris SAND104, Pichia pastoris SAND105, Pichia pastoris SAND106, Pichia pastoris SAND107, Pichia pastoris SAND108, Pichia pastoris SAND109, Pichia pastoris SAND110, Pichia pastoris SAND111, Pichia pastoris SAND112, Pichia pastoris SAND113, Pichia pastoris SAND114, Pichia pastoris Conversion of 3-keto-5-beta-cholanic acid (3-KCA) to 3-keto-7-beta-hydroxy-5-beta-cholanic acid (3-KUDCA) by strains Pichia pastoris SAND115, Pichia pastoris SAND116, Pichia pastoris SAND117, Pichia pastoris SAND118, Pichia pastoris SAND119, Pichia pastoris SAND120, and Pichia pastoris SAND121 is tested by induction of gene expression using standard methods. In one such method, YPD medium containing 100 μg / ml nourseothricin and 100 μg / ml zeocin is inoculated with a fresh single colony of the strain and incubated overnight at 30° C. with shaking at 250 RPM. Fresh BMMY medium containing 2 mM aminolevulinic acid, 100 μL / ml nourseothricin and 100 μg / ml zeocin is inoculated with 1 / 10 volume of the overnight culture and incubated at 30° C. with shaking at 250 RPM until an OD600 of 1.0 is reached.Add methanol to a final concentration of 0.5% (v / v) and 3-KCA to a final concentration of 1 mM and resume incubation at 30 °C for 2-3 days with shaking at 250 RPM.

[0134] The products, including 3-KUDCA, are extracted from the broth using standard methods: in one method, the culture is extracted into an equal volume of ethyl acetate, the pH is adjusted to less than 4 by the addition of acid, the ethyl acetate phase is separated, the solvent is then removed by evaporation, and the desired sterol is then purified using chromatography.

[0135] [Example 15] 3-KCA transformation using whole cells of Pichia pastoris strains Pichia pastoris SAND104 to Pichia pastoris SAND121 grown in BMG medium Pichia pastoris SAND104, Pichia pastoris SAND105, Pichia pastoris SAND106, Pichia pastoris SAND107, Pichia pastoris SAND108, Pichia pastoris SAND109, Pichia pastoris SAND110, Pichia pastoris SAND111, Pichia pastoris SAND112, Pichia pastoris SAND113, Pichia pastoris SAND114, Pichia pastoris Conversion of 3-KCA to 3-KUDCA by strains Pichia pastoris SAND115, Pichia pastoris SAND116, Pichia pastoris SAND117, Pichia pastoris SAND118, Pichia pastoris SAND119, Pichia pastoris SAND120, and Pichia pastoris SAND121 is tested by induction of gene expression using standard methods such as those described in W. Lu, J. Feng, X. Chen, et al., 2019 Appl. Environ. Microbiol. 85, e01182-19. In this method, 25 ml of BMG medium is inoculated with a fresh single colony of the strain and incubated at 30°C with shaking at 250 RPM to an OD600 of 10. Cells are harvested by centrifugation at 4000 x g for 5 minutes and suspended in BMM medium containing 2 mM aminolevulenic acid to an OD600 of 10. The culture is incubated at 20°C with shaking at 250 RPM for 5 days with the addition of methanol (1% v / v) every 24 hours.

[0136] The cells are harvested by centrifugation at 4000 x g for 5 minutes and resuspended in 30 ml of 50 mM potassium phosphate buffer, pH 7.5, containing 2 mM aminolevulinic acid and 1 mM 3-KCA. The cell suspension is incubated at 30°C for 3 days with shaking at 200 RPM, with the addition of methanol (1% v / v) every 24 hours.

[0137] The products, including 3-KUDCA, are extracted from the broth using standard methods: in one method, the culture is extracted into an equal volume of ethyl acetate, the pH is adjusted to less than 4 by the addition of acid, the ethyl acetate phase is separated, the solvent is then removed by evaporation, and the desired sterol is then purified using chromatography.

[0138] General Methods for Examples 16-21 Analysis of culture extracts Following solvent extraction of the liquid cultures described in the Examples, samples were analyzed for UDCA and 3-KUDCA production on an Agilent 1100 HPLC equipped with a Waters XSelect CSH C18 column (2.1 mm x 50 mm x 3.5 μm) fitted with a Waters VanGuard and Acquity in-line column filter and operated at 60°C. The mobile phase consisted of solvent A (0.005 M ammonium acetate, 0.012% formic acid) and solvent B (95% methanol, 5% water, 0.012% formic acid) at a flow rate of 1.0 mL / min. A gradient was run from 50% solvent B to 100% solvent B over 9.5 min. Samples were analyzed by UV at 212 nm and by MS using a Waters ZQ single quadrupole MS running in electrospray negative ion mode with a mass range of m / z 150-500.

[0139] Culture medium 2TY medium contains 16 g / L bactotryptone, 10 g / L yeast extract, and 5 g / L NaCl, and is sterilized by autoclaving. 2TY agar also contains 15 g / L agar.

[0140] Synthetic dextrose minimal medium contains 6.7 g / L of amino acid-free yeast nitrogen base, 20 g / L of dextrose, and 1.3 g / L of amino acid dropout powder, and is sterilized by autoclave. Synthetic dextrose minimal agar medium contains 20 g / L of agar.

[0141] Synthetic galactose minimal medium contains 6.7 g / L of amino acid-free yeast nitrogen base, 20 g / L of galactose, and 1.3 g / L of amino acid dropout powder, and is sterilized by autoclave. Synthetic galactose minimal agar medium contains 20 g / L of agar.

[0142] Transformation of Pichia pastoris Pichia pastoris (Komagataella phaffi NRRL Y-11430 / ATCC 76273, hereafter referred to as Pichia pastoris SAND101) was grown overnight at 30°C in 10 ml of YPD with shaking at 250 RPM. This culture was used to inoculate 500 ml of YPD to an OD of 0.1 and then incubated at 30°C with shaking at 250 RPM until an OD of 1.3-1.5 was reached. Cells were harvested by centrifugation at 2000 × g for 10 minutes at 4°C and resuspended in 100 ml of YPD supplemented with 20 ml of 1 M HEPES, pH 8.0, and 2.5 ml of 1 M DTT. The cells were incubated at 30°C for 15 minutes without shaking. Cold dH2O was added to a final volume of 500 ml, and the cells were harvested by centrifugation at 2000 x g for 10 minutes at 4°C. The cells were washed with 250 ml of cold dH2O and harvested by centrifugation at 2000 x g for 10 minutes at 4°C. The cells were washed with 20 ml of cold 1 M sorbitol and harvested by centrifugation at 2000 x g for 10 minutes at 4°C. The cells were resuspended in 500 μl of cold 1 M sorbitol. 100 ng of DNA was added to 40 μl of competent cells and transferred to a 2 mm gap electroporation cuvette pre-chilled on ice. The cells were electroporated using a BTRX ECM 630 decaying wave electroporation system using settings of 1500 V, 200 Ω, and 25 μF. 1 mL of cold 1 M sorbitol was immediately added, and the mixture was transferred to a sterile Eppendorf tube. The cells were allowed to regenerate with shaking at 30°C and 250 RPM for at least 30 minutes. The cells were then spread onto YPD agar plates containing the appropriate antibiotics and incubated at 30° C. for 2 days or until colonies were visible.

[0143] Transformation of Saccharomyces cerevisiae Saccharomyces cerevisiae YPH499 (Agilent) was grown overnight at 30°C in 10 ml of YPD with shaking at 250 RPM. This culture was used to inoculate 500 ml of YPD to an OD600 of 0.1 and then incubated at 30°C with shaking at 250 RPM until an OD600 of 1.3-1.5 was reached. Cells were harvested by centrifugation at 2000 x g for 10 minutes at 4°C and resuspended in 100 ml of YPD supplemented with 20 ml of 1 M HEPES, pH 8.0, and 2.5 ml of 1 M DTT. The cells were incubated at 30°C for 15 minutes without shaking. Cold dH2O was added to a final volume of 500 ml, and the cells were harvested by centrifugation at 2000 x g for 10 minutes at 4°C. The cells were washed with 250 ml of cold dH2O and collected by centrifugation at 2000 x g for 10 minutes at 4°C. The cells were washed with 20 ml of cold 1 M sorbitol and collected by centrifugation at 2000 x g for 10 minutes at 4°C. The cells were resuspended in 500 μl of cold 1 M sorbitol. 100 ng of DNA was added to 40 μl of competent cells and transferred to a 2 mm gap electroporation cuvette pre-chilled on ice. The cells were electroporated using a BTRX ECM 630 decaying wave electroporation system using settings of 1500 V, 200 Ω, and 25 μF. 1 mL of cold 1 M sorbitol was immediately added, and the mixture was transferred to a sterile Eppendorf tube. The cells were allowed to regenerate with shaking at 30°C and 250 RPM for at least 30 minutes. The cells were then spread onto synthetic dextrose minimal agar medium lacking uracil and then incubated at 30° C. for 3 days or until colonies were visible.

[0144] [Example 16] Construction of Pichia pastoris strains capable of expressing SEQ ID NO:2 and SEQ ID NO:32 Plasmid pSAND101 was constructed as follows: Plasmid pPICHOLI-1 (MoBiTec GmbH, Germany) was cleaved with restriction enzymes BsaI and PciI. SEQ ID NO: 34 was ordered as synthetic DNA (Integrated DNA Technologies) and inserted into the cleaved pPICHOLI-1 by infusion cloning (Takara Bio), followed by transformation of E. coli using standard methods. Transformants were plated onto 2TY agar containing 100 μg / mL nourseothricin. Correct assembly of pSAND101 was confirmed by restriction digestion.

[0145] Plasmid pSAND102 was constructed as follows: Plasmid pSAND101 was cleaved with restriction enzymes EcoRI and SalI. SEQ ID NO:35 was ordered as synthetic DNA (Twist Bioscience) and cleaved with restriction enzymes EcoRI and SalI. The digested synthetic DNA was inserted into cleaved pSAND101 by ligation according to standard methods. E. coli transformants were plated onto 2TY agar containing 100 μg / mL nourseothricin. Correct assembly of pSAND102 was confirmed by restriction digestion.

[0146] Plasmid pSAND112 was constructed as follows: Plasmid pPICHOLI-1 was cleaved with restriction enzymes EcoRI and SalI. SEQ ID NO:36 was ordered as synthetic DNA (Twist Bioscience) and cleaved with restriction enzymes EcoRI and SalI. The digested synthetic DNA was inserted into cleaved pPICHOLI-1 by ligation according to standard methods. E. coli transformants were plated onto 2TY agar containing 100 μg / mL Zeocin. Correct assembly of pSAND112 was confirmed by restriction digestion.

[0147] Plasmid pSAND102 was linearized by digestion with the restriction enzyme PmeI. Linearized pSAND102 was used to transform Pichia pastoris SAND101 by electroporation using standard methods. The resulting strain was labeled Pichia pastoris SAND102.

[0148] Plasmid pSAND112 was used to transform Pichia pastoris SAND102 by electroporation using standard methods, and the resulting strain was labeled Pichia pastoris SAND121.

[0149] [Example 17] Biotransformation of LCA to UDCA by Pichia pastoris Sand121 Pichia pastoris SAND121 was used as a seed culture by inoculating 25 mL of BMG medium supplemented with 100 μg / mL of Zeocin in a 250 mL Erlenmeyer flask and incubating at 30°C with shaking at 250 RPM for 2 days.

[0150] Cells from the seed culture were harvested by centrifugation and used to inoculate 250 mL of BMM containing 2 mM 5-aminolevulinic acid (5-ALA) in a 1 L Erlenmeyer flask to an OD595 of 1.0, incubated at 20°C for 5 days, and used as the expression culture. The expression culture was shaken at 170 RPM for 1 day and then at 250 RPM for the remaining 4 days. Methanol was fed to the expression culture daily to a concentration of 1% v / v.

[0151] Cells from 80 mL of expression culture were harvested by centrifugation, suspended in 30 mL of filter-sterilized potassium phosphate buffer at pH 7.5, and transferred to a 250 mL Erlenmeyer flask. Cells from 80 mL of expression culture were harvested by centrifugation, suspended in 30 mL of filter-sterilized potassium phosphate buffer at pH 9, and transferred to a 250 mL Erlenmeyer flask. To each flask, 0.25 mL of an aqueous 5-ALA solution (200 mM) and 0.35 mL of methanol containing 38.8 mg / mL of LCA were added. Both flasks, used as bioconversion cultures, were incubated at 30°C with shaking at 250 RPM. The bioconversion cultures were fed daily with 0.35 mL of methanol, and incubation was continued for two days. The bioconversion cultures were then fed with 1.0 mL of methanol, and incubation was continued for three days.

[0152] A 500 μL sample was removed from the bioconversion culture and extracted with an equal volume of ethyl acetate containing 0.1% formic acid by shaking for 45 minutes. The phases were separated by centrifugation, and 20 μL of the solvent phase was transferred to a clean tube and evaporated. The pellet was dissolved in 20 μL of methanol, diluted 10-fold with a mixture of 50% mobile phase solution A and 50% mobile phase solution B, and analyzed by HPLC-MS (see General Methods). A peak with the same retention time and mass spectral profile as that seen in a parallel run of a UDCA standard was observed (see Figures 1 and 2).

[0153] The remaining bioconversion culture broth was transferred to a 50 mL falcon tube and stored at −20° C. for later isolation of UDCA (see Example 18).

[0154] [Example 18] Isolation of UDCA and comparison with authentic standards The bioconversion culture broth stored at -20°C described in Example 17 was thawed and centrifuged at 4500 RPM for 15 minutes. 100 mL of the resulting supernatant was decanted and extracted three times with an equal volume of ethyl acetate containing 0.1% formic acid with stirring for 45 minutes. The organic phases were pooled and evaporated under vacuum to yield a crude product weighing 179 mg.

[0155] The crude product was dissolved in 80 mL of ethyl acetate and dry-loaded onto 1.5 g of silica gel (Merck grade 9385, 200-400 mesh particle size) by removing the solvent in vacuo. The dried silica was poured onto the top of a 25 g pre-packed silica Biotage KP-Sil Snap cartridge (Biotage). The column was eluted with an ethyl acetate-hexane gradient from 10% ethyl acetate to 100% ethyl acetate over 10 column volumes. Fractions were collected and assayed by LCMS. Selected fractions were combined, and the solvent was evaporated on a rotary evaporator, yielding an extract weighing 11.3 mg.

[0156] The extract was then dissolved in acetonitrile (0.3 mL) and DMSO (0.7 mL) and loaded onto a 12 g Snap Ultra cartridge (Biotage) pre-equilibrated with a mixture of 25% acetonitrile and 75% water. The column was eluted with an acetonitrile-water gradient of 25% acetonitrile to 80% acetonitrile over 10 column volumes. Fractions were collected and then assayed by LC-MS. Selected fractions were pooled, analyzed by LCMS (see Figures 3 and 4), and then lyophilized to yield a white powder weighing 3.8 mg.

[0157] NMR spectroscopy of this sample in d4-methanol was performed and compared to a commercially available sample of UDCA (Sigma-Aldrich) run at the same time. NMR spectra were recorded on a Bruker 500 MHz DCH Cryoprobe Spectrometer at 298 K operating at 500.05 MHz and 125.75 MHz for 1H and 13C, respectively. The NMR spectrum of the UDCA commercial standard matched the sample NMR spectrum (see Figures 5, 6, 7, and 8).

[0158] [Example 19] Biotransformation of 3-KCA to 3-KUDCA by Pichia pastoris Sand121 Pichia pastoris SAND121 was used to inoculate 25 mL of BMG medium supplemented with 100 μg / mL nourseothricin and 100 μg / mL zeocin in a 250 mL Erlenmeyer flask and incubated at 30°C for 3 days with shaking at 250 RPM. 0.25 mL of 200 mM 5-ALA aqueous solution and 0.25 mL of methanol containing 37.6 mg / mL 3-ketolithocholic acid (3-KCA) were added to the culture, and incubation continued for 1 day as before. 800 μL of broth was removed from the culture and extracted with an equal volume of ethyl acetate containing 0.1% formic acid by shaking for 45 minutes. The phases were separated by centrifugation, and 400 μL of the solvent phase was transferred to a clean tube and evaporated. The pellet was dissolved in 400 μL of methanol by mixing for 10 minutes and centrifuged at 12,000 × g for 1 minute. 15 μL of the methanol solution was diluted 10-fold with a mixture of 50% mobile phase solution A and 50% mobile phase solution B and analyzed by HPLC-MS (see General Methods). A peak with the same retention time and mass spectral profile as that seen in a parallel run of a 3-KUDCA standard was observed (see Figures 9 and 10).

[0159] [Example 20] Construction of a Saccharomyces cerevisiae strain capable of expressing SEQ ID NO:2 and SEQ ID NO:32 Plasmid pSAND113, which expresses a gene encoding a P450 having the sequence of SEQ ID NO: 33 under the control of the Gal1 promoter and a gene encoding a P450 reductase having the sequence of SEQ ID NO: 3 under the control of the Gal10 promoter, was constructed as follows.

[0160] Plasmid pESC-URA (Agilent) was cleaved with restriction enzymes EcoRI and SpeI. An 837 bp fragment was amplified from plasmid pSAND102 using primers SEQ ID NO:37 and SEQ ID NO:38. This 837 bp fragment was inserted into EcoRI-SpeI-digested pESC-URA using the SLiCE cloning method (Zhang et al., 2014) to form an intermediate plasmid. The insertion and identity of the insert were confirmed by restriction digestion.

[0161] The intermediate plasmid was cleaved with restriction enzymes HindIII and SalI. A 1584 bp fragment was amplified from plasmid pSAND112 using primers SEQ ID NO:39 and SEQ ID NO:40. This 1584 bp fragment was inserted into the HindIII-SalI-digested intermediate plasmid using the SLiCE cloning method (Zhang et al., 2014) to form plasmid pSAND113. The insertion and identity of the insert were confirmed by restriction digestion.

[0162] Saccharomyces cerevisiae strain YPH499 (Agilent) was transformed with plasmid pSAND113 by electroporation using standard methods, after which the cell suspension was plated onto synthetic dextrose minimal agar medium lacking uracil and incubated at 30°C until colonies were visible. The resulting strain was designated Saccharomyces cerevisiae SAND122.

[0163] [Example 21] Bioconversion of LCA to UDCA by Saccharomyces cerevisiae SAND122 In a 50 mL Falcon tube, 7 mL of synthetic dextrose minimal medium lacking uracil was inoculated with Saccharomyces cerevisiae SAND122 and incubated at 30°C with shaking at 250 RPM for 24 hours to serve as the seed culture.

[0164] The 1 mL seed culture was briefly centrifuged to harvest the cells. The supernatant was discarded, and the remaining cell pellet was suspended in 5 mL of synthetic galactose minimal medium lacking uracil in a 50 mL Falcon tube capped with a foam stopper. This culture was incubated at 30°C with shaking at 250 RPM for 24 hours and used as the expression culture.

[0165] Four mL of the expression culture was briefly centrifuged to harvest the cells. The supernatant was discarded, and the remaining cell pellet was suspended in 5 mL of bioconversion buffer (0.1 M potassium phosphate buffer at pH 10, 1% galactose, and 650 mg / L LCA) in a 50 mL Falcon tube capped with a foam stopper. This suspension was incubated at 30° C. with shaking at 250 RPM for 72 hours and used as the bioconversion culture.

[0166] A 500 μL sample was removed from the bioconversion culture and extracted with an equal volume of ethyl acetate containing 0.1% formic acid by shaking for 45 minutes. The phases were separated by centrifugation, and 20 μL of the solvent phase was transferred to a clean tube and evaporated. The pellet was dissolved in 20 μL of methanol, diluted 10-fold with a mixture of 50% mobile phase solution A and 50% mobile phase solution B, and analyzed by HPLC-MS (see General Methods). A peak with the same retention time and mass spectral profile as that seen in a parallel run of a UDCA standard was observed (see Figures 11 and 12).

[0167] References Zhang, Y., Werling, U., Ederlmann, W. (2014). Seamless Ligation Cloning Extract (SLiCE) Cloning Method. Methods in Molecular Biology 1116, 235-244.

[0168] Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims.

Claims

1. 1. A process for converting LCA or 3-KCA, or a carboxylic ester, carboxylamide or carboxylate salt thereof, to UDCA or 3-KUDCA, or a carboxylic ester, carboxylamide or carboxylate salt thereof, comprising the steps of: contacting said LCA or 3-KCA, or a carboxylic acid ester, carboxylamide or carboxylate salt thereof, with a 7β-hydroxylase system in the presence of yeast, or an extract or lysate thereof; the 7β-hydroxylase system is not native to the yeast; method.

2. 2. The method of claim 1, wherein the yeast is selected from the genera Saccharomyces and Pichia.

3. 2. The method of claim 1, wherein the yeast is selected from Saccharomyces cerevisiae and Pichia pastoris.

4. 2. The method of claim 1, wherein the 7β-hydroxylation system comprises a P450 oxidoreductase ("CPR") enzyme and a P450 7-beta-hydroxylase ("CYP") enzyme, wherein the CYP enzyme is not native to the yeast, and wherein the CPR enzyme may or may not be native to the yeast.

5. the CYP enzyme is a CYP-encoding nucleic acid sequence selected from SEQ ID NO:8; SEQ ID NO:11; SEQ ID NO:14; SEQ ID NO:17; SEQ ID NO:20; SEQ ID NO:23; SEQ ID NO:26; SEQ ID NO:29; and SEQ ID NO:32; or A nucleic acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the preceding nucleic acid sequences. The method of claim 4, wherein the gene is encoded by

6. The CPR enzyme is a CYP-encoding nucleic acid sequence selected from SEQ ID NO:2 and SEQ ID NO:5; or A nucleic acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the preceding nucleic acid sequences. The method of claim 4, wherein the gene is encoded by

7. the CYP enzyme is a CYP amino acid sequence selected from SEQ ID NO:9; SEQ ID NO:12; SEQ ID NO:15; SEQ ID NO:18; SEQ ID NO:21; SEQ ID NO:24; SEQ ID NO:27; SEQ ID NO:30; or SEQ ID NO:33; or An amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the preceding amino acid sequences. The method of claim 4 , comprising:

8. The CPR enzyme has a CPR amino acid sequence selected from SEQ ID NO:3 and SEQ ID NO:6, or An amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the preceding amino acid sequences. The method of claim 4 , comprising:

9. 2. The method of claim 1, wherein the 7β-hydroxylase system comprises a P450 7-beta-hydroxylase ("CYP") enzyme native to F. graminearum or Gibberella zeae, preferably Gibberella zeae PH1 or Gibberella zeae VKM2600, most preferably Gibberella zeae VKM2600.

10. 8. The method of claim 7, comprising contacting the LCA or a carboxylic ester, carboxylamide or carboxylate salt thereof with the 7β-hydroxylase system to produce UDCA or a carboxylic ester, carboxylamide or carboxylate salt thereof.

11. 8. The method of claim 7, comprising contacting the 3-KCA or a carboxylic ester, carboxylamide or carboxylate salt thereof with the 7β-hydroxylase system to produce 3-KUDCA or a carboxylic ester, carboxylamide or carboxylate salt thereof.

12. 12. The method of claim 11, further comprising reducing the 3-KUDCA or a carboxylic ester, carboxylamide or carboxylate salt thereof to UDCA or a carboxylic ester, carboxylamide or carboxylate salt thereof.

13. A nucleic acid sequence selected from SEQ ID NO:8; SEQ ID NO:11; SEQ ID NO:14; SEQ ID NO:17; SEQ ID NO:20; SEQ ID NO:23; SEQ ID NO:26; SEQ ID NO:29; or SEQ ID NO:32; or A nucleic acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the preceding sequences. A plasmid comprising:

14. The plasmid of claim 13, which is under the control of the AOX1 promoter and AOX1 terminator sequences.

15. A CYP-encoding nucleic acid sequence selected from SEQ ID NO:8; SEQ ID NO:11; SEQ ID NO:14; SEQ ID NO:17; SEQ ID NO:20; SEQ ID NO:23; SEQ ID NO:26; SEQ ID NO:29; and SEQ ID NO:32; or A nucleic acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the preceding nucleic acid sequences. An organism transformed by.

16. A CPR-encoding nucleic acid sequence comprising SEQ ID NO:2 or SEQ ID NO:5, or A nucleic acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to any of the preceding nucleic acid sequences.

16. The organism of claim 15 further transformed by

17. 16. An organism according to claim 15, which is a yeast, preferably of the genus Saccharomyces or Pichia, more preferably Saccharomyces cerevisiae or Pichia pastoris.

18. The method of claim 10, further comprising processing the UDCA into a final dosage form.

19. The method of claim 12, further comprising processing the UDCA into a final dosage form.